Evgenii A. Osmanov

865 total citations
22 papers, 493 citations indexed

About

Evgenii A. Osmanov is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Evgenii A. Osmanov has authored 22 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 7 papers in Hematology. Recurrent topics in Evgenii A. Osmanov's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Viral-associated cancers and disorders (6 papers). Evgenii A. Osmanov is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Viral-associated cancers and disorders (6 papers). Evgenii A. Osmanov collaborates with scholars based in Russia, United States and United Kingdom. Evgenii A. Osmanov's co-authors include Helgi van de Velde, Olga Samoilova, Xiaonan Hong, Huiqiang Huang, Tadeusz Robak, Ting Liu, Noppadol Siritanaratkul, Halyna Pylypenko, Brendan Rooney and Rumiko Okamoto and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Evgenii A. Osmanov

18 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evgenii A. Osmanov Russia 6 352 316 207 110 70 22 493
Huiqiang Huang China 8 297 0.8× 267 0.8× 149 0.7× 100 0.9× 51 0.7× 20 460
Alma María Rodríguez United States 5 344 1.0× 286 0.9× 208 1.0× 215 2.0× 109 1.6× 7 597
Simon Rule United Kingdom 7 321 0.9× 242 0.8× 189 0.9× 62 0.6× 29 0.4× 12 390
Dipti Patel‐Donnelly United States 13 216 0.6× 197 0.6× 133 0.6× 130 1.2× 146 2.1× 27 433
Brian Munneke United States 7 219 0.6× 170 0.5× 161 0.8× 61 0.6× 38 0.5× 13 337
Sverker Hasselblom Sweden 14 320 0.9× 209 0.7× 115 0.6× 103 0.9× 46 0.7× 25 494
Eugene Zhu United States 8 155 0.4× 164 0.5× 123 0.6× 81 0.7× 52 0.7× 11 301
Lixia Pei United States 10 224 0.6× 312 1.0× 144 0.7× 176 1.6× 180 2.6× 27 476
Nadine Juge‐Morineau France 12 250 0.7× 266 0.8× 149 0.7× 162 1.5× 227 3.2× 18 553
Richard H. van der Jagt United States 10 740 2.1× 484 1.5× 504 2.4× 91 0.8× 98 1.4× 19 886

Countries citing papers authored by Evgenii A. Osmanov

Since Specialization
Citations

This map shows the geographic impact of Evgenii A. Osmanov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgenii A. Osmanov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgenii A. Osmanov more than expected).

Fields of papers citing papers by Evgenii A. Osmanov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgenii A. Osmanov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgenii A. Osmanov. The network helps show where Evgenii A. Osmanov may publish in the future.

Co-authorship network of co-authors of Evgenii A. Osmanov

This figure shows the co-authorship network connecting the top 25 collaborators of Evgenii A. Osmanov. A scholar is included among the top collaborators of Evgenii A. Osmanov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgenii A. Osmanov. Evgenii A. Osmanov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lyubimova, N. V., et al.. (2022). BIOCHEMICAL PROFILE OF BENCE-JONES TYPE MULTIPLE MYELOMA. Russian Clinical Laboratory Diagnostics. 67(10). 570–574. 1 indexed citations
2.
Менделеева, Л. П., et al.. (2021). Multiple myeloma. SHILAP Revista de lepidopterología. 22(4). 6–28. 11 indexed citations
3.
4.
Osmanov, Evgenii A., et al.. (2020). Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice. Russian Journal of Pediatric Hematology and Oncology. 7(3). 86–93.
5.
Osmanov, Evgenii A., et al.. (2020). The experience of reforming primary health care in conditions of increasing of population average age. Problems of Social Hygiene Public Health and History of Medicine. 28(6). 1374–1379. 1 indexed citations
6.
Tumyan, Gayane, Evgenii A. Osmanov, I V Poddubnaya, et al.. (2020). Follicular lymphoma. SHILAP Revista de lepidopterología. 22(2). 34–51. 1 indexed citations
7.
Osmanov, Evgenii A., et al.. (2020). Solitary (extramedullary) plasmocytoma. Clinical recommendations. SHILAP Revista de lepidopterología. 22(1). 7–15. 1 indexed citations
8.
Воробьев, В. И., et al.. (2020). Mantle cell lymphoma. SHILAP Revista de lepidopterología. 22(3). 6–23.
9.
Osmanov, Evgenii A., et al.. (2019). Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. Russian Journal of Biotherapy. 18(1). 50–59.
10.
Tumyan, Gayane, et al.. (2017). Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program. Clinical oncohematology. 10(2). 150–157. 1 indexed citations
11.
Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2017). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leukemia & lymphoma. 60(1). 172–179. 9 indexed citations
12.
Osmanov, Evgenii A., et al.. (2016). BCR-ABL GENE KINASE DOMAIN MUTATION FREQUENCY IN IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS. Russian Journal of Biotherapy. 15(4). 102–109. 2 indexed citations
13.
Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901. 98 indexed citations
14.
Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2015). Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. New England Journal of Medicine. 372(10). 944–953. 261 indexed citations
15.
Osmanov, Evgenii A., et al.. (2014). Tumor-associated cytotoxic lymphocytes and macrophages as predictive factors in follicular lymphoma. Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology. 8(2). 198–205. 2 indexed citations
16.
17.
Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations
18.
Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2010). A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. Blood. 116(21). 857–857. 11 indexed citations
19.
Смирнова, К. В., et al.. (2008). [Mutations of the Epstein-Barr virus LMP1 gene mutations in Russian patients with lymphoid pathology and healthy individuals].. PubMed. 53(1). 10–6. 5 indexed citations
20.
Poddubnaya, I V, et al.. (2007). R-CHOP compared with CHOP in patients with diffuse large B-cell lymphoma (DLCL): Russian experience. Journal of Clinical Oncology. 25(18_suppl). 18536–18536. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Alma María Rodríguez Breakdown of academic impact, for papers by Simon Rule Breakdown of academic impact, for papers by Dipti Patel‐Donnelly Breakdown of academic impact, for papers by Brian Munneke Breakdown of academic impact, for papers by Sverker Hasselblom Breakdown of academic impact, for papers by Eugene Zhu Breakdown of academic impact, for papers by Lixia Pei Breakdown of academic impact, for papers by Nadine Juge‐Morineau Breakdown of academic impact, for papers by Richard H. van der Jagt
Rankless by CCL
2026